ChromaDex (NASDAQ:CDXC – Get Free Report)‘s stock had its “buy” rating restated by HC Wainwright in a research note issued to investors on Monday,Benzinga reports. They presently have a $11.00 price objective on the stock. HC Wainwright’s target price points to a potential upside of 40.31% from the company’s current price.
Several other equities analysts have also recently commented on the stock. LADENBURG THALM/SH SH increased their price target on shares of ChromaDex from $6.80 to $8.10 and gave the stock a “buy” rating in a research report on Wednesday, March 5th. StockNews.com downgraded ChromaDex from a “strong-buy” rating to a “buy” rating in a report on Thursday, March 6th.
Read Our Latest Stock Report on ChromaDex
ChromaDex Price Performance
Institutional Inflows and Outflows
Large investors have recently modified their holdings of the business. Squarepoint Ops LLC acquired a new stake in ChromaDex during the fourth quarter worth about $555,000. Two Sigma Investments LP bought a new position in shares of ChromaDex during the fourth quarter valued at approximately $675,000. State of Wyoming acquired a new stake in shares of ChromaDex during the 4th quarter worth approximately $39,000. Sherbrooke Park Advisers LLC bought a new stake in shares of ChromaDex in the 4th quarter worth approximately $94,000. Finally, ProShare Advisors LLC acquired a new position in ChromaDex during the 4th quarter valued at approximately $74,000. 15.41% of the stock is currently owned by institutional investors.
ChromaDex Company Profile
ChromaDex Corporation operates as a bioscience company focusing on developing healthy aging products. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products.
Recommended Stories
- Five stocks we like better than ChromaDex
- Insider Selling Explained: Can it Inform Your Investing Choices?
- Meta Platforms: Can LLaMA Drive Long-Term Stock Growth?
- What to Know About Investing in Penny Stocks
- 3 Unique and Dominant Consumer Staples ETF Plays
- The Risks of Owning Bonds
- 3 Dividend Stocks Offering Higher Yields and Bullish Forecasts
Receive News & Ratings for ChromaDex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ChromaDex and related companies with MarketBeat.com's FREE daily email newsletter.